Multi-cancer Early Detection (MCED) assays represent a new paradigm in cancer screening with the potential to deliver on the long-unfulfilled promise of earlier detention of many cancers with a single test. However, introducing such technology at scale has the potential to create new challenges for patients, providers, and health systems. In this session we will explore ways to translate technology into action and build your organizations' tool box.
Innovation in Personalized Medicine & Population Health Speaker Series
Multi-Cancer Early Detection
Supporting Patients & Providers in Navigating the New Paradigm
Tuesday, December 14, 2021
4:00 - 5:00 PM ET
Learning Objectives:
- Review the potential impact of MCED testing across a broad population of higher risk individuals.
- Explore the challenges of implementing MCED programs at the health system and provider level.
- Discuss potential strategies to support patients and providers in navigating the new paradigm.
Featuring:
Dax Kurbegov, MD
Vice President
Physician-in-Chief of Clinical Operations
Sarah Cannon
Candace Westgate, DO, MPH, FACOG
Founder and Director, AHEAD
Adventist Health
Moderated by:
Alexis Skoufalos, EdD
Associate Dean, Strategic Development
Program Director, DHSc in Population Health
Jefferson College of Population Health